MiMedx Group MDXG Surgical — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MiMedx Group in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about MiMedx Group's surgical — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MiMedx Group's surgical — net sales?
- MiMedx Group (MDXG) reported surgical — net sales of $36.37M in Q1 2026.
- How has MiMedx Group's surgical — net sales changed year-over-year?
- MiMedx Group's surgical — net sales increased by 13.2% year-over-year, from $32.13M to $36.37M.
- What is the long-term trend for MiMedx Group's surgical — net sales?
- Over 3 years (2022 to 2025), MiMedx Group's surgical — net sales has grown at a 15.7% compound annual growth rate (CAGR), from $91.87M to $142.3M.
- What does surgical — net sales mean?
- This metric represents the total revenue generated from the sale of regenerative biomaterials and bioimplants specifically utilized within surgical, sports medicine, and orthopedic clinical applications. It serves as a key indicator of the company's market penetration and adoption rates for internal-use allografts and related surgical products. Growth in this segment reflects the company's ability to expand its footprint in high-acuity medical procedures and compete effectively within the broader surgical intervention market.